Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer

被引：1
|
作者：
Cardoso, F. [1 ]
Canon, J. L. [2 ]
Amadori, D. [3 ]
Dirix, L. [4 ]
Villa, E. [5 ]
Aldrighetti, D. [5 ]
Machiels, J. P. [6 ]
Verkh, L. [7 ]
Kern, K. [7 ]
Giorgetti, C. [8 ]
机构：
[1] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium
[2] Grand Hop Charleroi, Dept Hematol Oncol, Charleroi, Belgium
[3] IRST, Meldola, Italy
[4] AZ ST Augustinus, Iridium Kankernetwerk, Antwerp, Belgium
[5] IRCCS Fdn San Raffaele Monte Tabor, Unita Operat Oncol Med, Milan, Italy
[6] Clin Univ St Luc, Ctr Canc, Univ Catholique Louvain, B-1200 Brussels, Belgium
[7] Pfizer Oncol, Dev, La Jolla, CA USA
[8] Pfizer Oncol, Dev, Milan, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70967-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：283 / 283
页数：1
相关论文
共 50 条
  • [21] The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
    Takahashi, Masato
    Ohtani, Shoichiro
    Nagai, Shigenori E.
    Takashima, Seiki
    Yamaguchi, Miki
    Tsuneizumi, Michiko
    Komoike, Yoshifumi
    Osako, Tomofumi
    Ito, Yoshinori
    Ikeda, Masahiko
    Ishida, Kazushige
    Nakayama, Takahiro
    Takashima, Tsutomu
    Asakawa, Takashi
    Matsumoto, Sho
    Shimizu, Daisuke
    Masuda, Norikazu
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 125 - 134
  • [22] The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
    Masato Takahashi
    Shoichiro Ohtani
    Shigenori E. Nagai
    Seiki Takashima
    Miki Yamaguchi
    Michiko Tsuneizumi
    Yoshifumi Komoike
    Tomofumi Osako
    Yoshinori Ito
    Masahiko Ikeda
    Kazushige Ishida
    Takahiro Nakayama
    Tsutomu Takashima
    Takashi Asakawa
    Sho Matsumoto
    Daisuke Shimizu
    Norikazu Masuda
    Breast Cancer Research and Treatment, 2021, 185 : 125 - 134
  • [23] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Fadi Farhat
    Joseph G. Kattan
    Marwan Ghosn
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1069 - 1077
  • [24] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Farhat, Fadi
    Kattan, Joseph G.
    Ghosn, Marwan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
  • [25] Phase II clinical trial of first-line eribulin plus trastuzumab for advanced or recurrent HER2-positive breast cancer
    Sakaguchi, K.
    Nakatsukasa, K.
    Taguchi, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 99 - 99
  • [26] Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
    Sakaguchi, Koichi
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Kato, Makoto
    Sakuyama, Akira
    Matsuda, Takayuki
    Tsunoda, Nobuyuki
    Fujiwara, Ikuya
    Yamaguchi, Masahide
    Tanaka, Hiroki
    Onishi, Kazuyoshi
    Onishi, Mie
    Yoshino, Yuji
    Kikuchi, Takashi
    Taguchi, Tetsuya
    ANTICANCER RESEARCH, 2018, 38 (07) : 4073 - 4081
  • [27] Trastuzumab as first-line therapy for metastatic breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 776 - 776
  • [28] Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E. A.
    Lopez-Vega, J. M.
    Del Mastro, L.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    CANCER RESEARCH, 2013, 73
  • [29] Prognostic value of natural killer cell activity for patients with HER2+advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab
    Cho, Hyungwoo
    Ryu, Min-Hee
    Lee, Hyung Eun
    Kim, Hyung-Don
    Kang, Yoon-Koo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (04) : 829 - 838
  • [30] An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer
    Kozloff, M.
    Chuang, E.
    Starr, A.
    Gowland, P. A.
    Cataruozolo, P. E.
    Collier, M.
    Verkh, L.
    Huang, X.
    Kern, K. A.
    Miller, K.
    ANNALS OF ONCOLOGY, 2010, 21 (07) : 1436 - 1441
12345